Synthesis: PARP inhibitors in BRCA-mutated metastatic TNBC

Evidence grades (GRADE-adapted): A high — multiple well-conducted RCTs or systematic reviews converge. B moderate — single pivotal RCT or consistent observational evidence. C limited — single observational study, mechanistic, or expert consensus. D preclinical / hypothesis-generating.

Synthetic lethality in one paragraph

Cells have two principal mechanisms for repairing DNA double-strand breaks: error-prone non-homologous end joining (NHEJ) and high-fidelity homologous recombination (HR). BRCA1 and BRCA2 are essential components of the HR pathway. Cells with biallelic loss of BRCA1 or BRCA2 (the situation in tumors where one allele is germline-mutated and the second is somatically lost or methylated) depend on backup repair pathways. PARP enzymes (PARP1, PARP2) are central to single-strand break repair; their inhibition causes unrepaired single-strand breaks to encounter replication forks and convert into double-strand breaks that an HR-deficient cell cannot repair, producing cell death. HR-proficient normal cells repair the double-strand breaks via HR and survive. This is "synthetic lethality" — a therapeutic strategy where each defect alone is tolerated but the combination is lethal^[1]A. The first clinical demonstration in BRCA-mutated cancer was Fong 2009^[2]A; the first breast-cancer randomized confirmation came eight years later with OlympiAD.

OlympiAD (olaparib)

Robson and colleagues randomized 302 patients with germline-BRCA-mutated HER2-negative metastatic breast cancer 2:1 to olaparib 300 mg twice daily vs single-agent chemotherapy of physician's choice (capecitabine, eribulin, or vinorelbine)^[3]A. Approximately 50% of enrolled patients were TNBC (the remainder were HR+/HER2−). Enrollment required no more than two prior chemotherapies for metastatic disease.

• Primary endpoint PFS: 7.0 vs 4.2 months (HR 0.58; 95% CI 0.43–0.80; p<0.001)
• Objective response rate: 59.9% vs 28.8%
• Median OS (final analysis 2019): 19.3 vs 17.1 months (HR 0.90; not significant); subgroup analysis suggested OS benefit concentrated in first-line metastatic patients
• Quality-of-life endpoints: superior with olaparib across HRQoL domains

The FDA approved olaparib for germline-BRCA-mutated HER2-negative metastatic breast cancer in January 2018; EMA approval followed in April 2019.

EMBRACA (talazoparib)

Litton and colleagues randomized 431 patients with the same enrollment criteria as OlympiAD (germline BRCA1/2, HER2-negative metastatic) 2:1 to talazoparib 1 mg daily vs single-agent physician's-choice chemotherapy^[4]A. About 45% of patients were TNBC.

• Primary endpoint PFS: 8.6 vs 5.6 months (HR 0.54; 95% CI 0.41–0.71; p<0.001)
• Objective response rate: 62.6% vs 27.2%
• Median OS (final analysis 2020): 19.3 vs 19.5 months (HR 0.85; not significant)
• Patient-reported outcomes: superior with talazoparib

Regulatory approvals followed: FDA in October 2018; EMA in 2019. Head-to-head data between olaparib and talazoparib do not exist; cross-trial comparison numerically favors talazoparib on PFS but the toxicity profiles differ (more myelosuppression with talazoparib; more nausea with olaparib). Choice is typically driven by toxicity considerations and patient-specific factors.

Toxicity profile of PARP inhibitors

Both olaparib and talazoparib have characteristic on-target toxicities reflecting widespread PARP activity in normal cells:

• Hematologic toxicity — anemia (most common; ~30–40% any-grade, 10–15% grade 3+), thrombocytopenia, neutropenia. More prominent with talazoparib than olaparib. Frequent dose-modification reason.
• Gastrointestinal — nausea (~50% any-grade), fatigue, diarrhea. More prominent with olaparib than talazoparib.
• Myelodysplastic syndrome / acute myeloid leukemia (MDS/AML) — rare but serious; observed in < 1% of metastatic-setting patients but more concerning in adjuvant-setting long-term treatment. Risk increases with prior alkylating-agent exposure.
• Pneumonitis — uncommon; requires evaluation if respiratory symptoms develop.
• Hypersensitivity / skin reactions — uncommon.

Beyond germline BRCA — HRD, somatic BRCA, PALB2

A persistent question since OlympiAD: do PARP inhibitors benefit patients with broader homologous-recombination deficiency, beyond germline BRCA1/2? Multiple investigations have addressed this:

• Somatic BRCA mutations — biologically should behave similarly to germline BRCA mutations once biallelic loss is established. Tutt 2018 reported responses to PARP inhibition in somatic-BRCA-mutated TNBC^[5]B. NCCN guidelines now recommend tumor (somatic) BRCA testing alongside germline testing; FDA label expansions have followed in some other indications.
• PALB2 mutations — PALB2 is required for BRCA2 function in HR; biallelic PALB2 loss should produce HR deficiency similar to BRCA loss. The TALA-PALB2 expansion (Gruber 2022)^[6]B showed substantive responses to talazoparib in PALB2-mutated breast cancer including TNBC. Confirmatory randomized data are pending.
• HRD score-based selection — commercial HRD assays (Myriad myChoice, Foundation Medicine FoundationFocus, Caris MI Profile) measure loss-of-heterozygosity, telomeric allelic imbalance, and large-scale state transitions to produce a composite HRD score. In ovarian cancer this approach has clear predictive validity. In TNBC, HRD-positive non-BRCA-mutant patients have shown some benefit from PARP inhibition in single-arm trials but the magnitude is more modest than in BRCA-mutant patients, and randomized confirmation is lacking^[7]C.
• Other HR-pathway genes (ATM, CHEK2, BARD1, BRIP1, RAD51 family) — PARP-inhibitor activity is more variable across these. Patient-level decisions are typically guided by genetic counselor and oncology consensus rather than approved indications.

Sequencing with platinum chemotherapy

Platinum chemotherapy (carboplatin, cisplatin) also exploits HR deficiency — platinum-induced DNA crosslinks require HR for repair. The TNT trial demonstrated platinum benefit in germline-BRCA-mutated TNBC^[8]A (see first-line metastatic synthesis). The clinical question is whether platinum should precede or follow PARP inhibition.

Observational data suggest:

• PARP-inhibitor benefit is maintained after platinum exposure but with reduced magnitude. Olaparib response rate in platinum-naive patients ~60%; in platinum-exposed patients ~40%^[3].
• Conversely, platinum response is generally maintained after PARP-inhibitor exposure, though with shorter duration.
• Clinical preference is increasingly to use PARP inhibitor before platinum for the metastatic-naive patient, since (a) platinum is also effective later, and (b) PARP-inhibitor effectiveness is partially compromised by acquired resistance that emerges during platinum therapy.

OlympiA — adjuvant olaparib in early-stage residual disease

Tutt and colleagues randomized 1,836 patients with germline BRCA1/2 mutations and high-risk early-stage breast cancer (residual disease after neoadjuvant chemotherapy, or high-risk pT3/N+ after adjuvant chemotherapy) to olaparib 300 mg twice daily for 1 year vs placebo^[9]A. Approximately 80% were TNBC.

• 3-year iDFS (primary endpoint): 85.9% vs 77.1% (HR 0.58)
• 3-year distant DFS: 87.5% vs 80.4% (HR 0.57)
• OS update (2022): 89.8% vs 86.4% at 4 years (HR 0.68; p=0.009)
• Tolerability acceptable; no excess of MDS/AML at the 3.5-year follow-up

OlympiA established adjuvant olaparib for 1 year as standard of care in germline-BRCA-mutated, HER2-negative, high-risk early-stage breast cancer following completion of standard neoadjuvant or adjuvant chemotherapy. FDA approval came in March 2022. Implementation in the KEYNOTE-522 era (where adjuvant pembrolizumab is also given) creates a multi-drug adjuvant regimen with operational complexity: pembrolizumab + olaparib + capecitabine all simultaneously is not formally tested, though the agents have different toxicity profiles and the combination is generally tolerated.

Acquired resistance mechanisms

Resistance to PARP inhibitors emerges in nearly all patients who initially respond. Documented mechanisms in breast and ovarian cancer^[10]B:

• BRCA reversion mutations — secondary intragenic mutations that restore BRCA reading frame and HR function. Detectable in ctDNA in approximately 20–30% of resistant patients.
• Loss of 53BP1, REV7, or shieldin complex components — restores HR by allowing end resection that BRCA1 normally regulates.
• Increased PARP-trapping resistance mechanisms — including ABCB1 (P-glycoprotein) overexpression, BRCAness suppression via NF-κB or other pathways.
• Stabilization of replication forks — via PTIP loss or other replication-fork-protection alterations.

Therapeutic strategies to overcome these resistance mechanisms (combination with WEE1 inhibitors, ATR inhibitors, or POLQ inhibitors) are in early-phase clinical trials.

Evidence table

Open questions and active investigation

• HRD-based selection beyond BRCA. Despite extensive investigation, no randomized trial has yet definitively demonstrated PARP-inhibitor benefit in HRD-positive non-BRCA TNBC patients at the level seen in BRCA-mutant patients. Whether better HRD assays or signature-based predictors will eventually identify the right non-BRCA subset remains an active research direction.
• PARP inhibitor combinations. Combinations with IO (pembrolizumab + olaparib in MEDIOLA/KEYLYNK-009), with WEE1/ATR inhibitors, with antiangiogenics, and with capecitabine are under investigation. None has yet shown clear advantage over PARP monotherapy.
• OlympiA + pembrolizumab adjuvant. The combination of adjuvant olaparib (for BRCA+) plus adjuvant pembrolizumab (for KEYNOTE-522 patients) is increasingly common in clinical practice but has not been formally tested in randomized trials. Long-term safety and efficacy data are accumulating.
• Earlier PARP inhibitor in metastatic, pre-platinum. Should germline-BRCA+ patients with metastatic TNBC start with PARP inhibitor before chemotherapy, given the platinum-pretreatment reduction in PARP response? Current ESMO/NCCN guidance leaves this choice to individual judgment; head-to-head trial data are lacking.
• Beyond PARP: POLθ and other targets. POLθ inhibitors target a backup repair pathway that BRCA-deficient cells use. Early trials (POLQ inhibitors) show single-agent activity in BRCA-mutant cancers and synergy with PARP inhibition. Could expand the target population or overcome resistance.
• Reversion-mutation detection via ctDNA. Serial ctDNA monitoring for BRCA reversion mutations during PARP-inhibitor treatment is technically feasible and could guide treatment switching. Clinical implementation is in early stages; whether early switching improves outcomes is unknown.

For the first-line metastatic decision tree, see First-line metastatic synthesis. For other metastatic options, see Sacituzumab govitecan (ASCENT) and Trastuzumab deruxtecan (DESTINY-Breast04). For the patient-layer companion, see Treatment options.

References

Each citation links to the original publication via DOI. The same records are searchable in the evidence library by title or DOI.

1. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434(7035):913–917. doi:10.1038/nature03443. ↩
2. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med. 2009;361(2):123–134. doi:10.1056/NEJMoa0900212. ↩
3. Robson M, Im SA, Senkus E, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation (OlympiAD). N Engl J Med. 2017;377(6):523–533. doi:10.1056/NEJMoa1706450. ↩
4. Litton JK, Rugo HS, Ettl J, et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation (EMBRACA). N Engl J Med. 2018;379(8):753–763. doi:10.1056/NEJMoa1802905. ↩
5. Tung NM, Robson ME, Ventz S, et al. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. J Clin Oncol. 2020;38(36):4274–4282. doi:10.1200/JCO.20.02151. ↩
6. Gruber JJ, Afghahi A, Timms K, et al. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes (TALA-PALB2). Nat Cancer. 2022;3(10):1181–1191. doi:10.1038/s43018-022-00439-1. ↩
7. Telli ML, Timms KM, Reid J, et al. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22(15):3764–3773. doi:10.1158/1078-0432.CCR-15-2477. ↩
8. Tutt A, Tovey H, Cheang MCU, et al. Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628–637. doi:10.1038/s41591-018-0009-7. ↩
9. Tutt ANJ, Garber JE, Kaufman B, et al. Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer (OlympiA). N Engl J Med. 2021;384(25):2394–2405. doi:10.1056/NEJMoa2105215. ↩
10. Noordermeer SM, van Attikum H. PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells. Trends Cell Biol. 2019;29(10):820–834. doi:10.1016/j.tcb.2019.07.008. ↩

Last reviewed: 2026-06-04. Researcher-layer synthesis page. Evidence grades follow the GRADE-adapted rubric defined at the top of this page.